as of —
₹—
Change
—
Day Open
₹—
Day High
₹—
Day Low
₹—
NSE Close — 28 Sep 2026
₹479.3
Change
+10.9 (2.33%)
Open
₹470.0
Prev. Close
₹468.4
Day High
₹497.55
Day Low
₹426.3
Volume Analysis
Traded
2,216,498
Delivered
16,863
Delivery %
44.69%
End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.
Strengths, Weaknesses, Opportunities & Threats
Strengths (1)
- •Promoter holding is rising
Weaknesses (0)
No signal for this stock
Opportunities (0)
No signal for this stock
Threats (0)
No signal for this stock
Rule-based signals from the fundamentals below — not investment advice.
Pivot Levels
| Type | R3 | R2 | R1 | Pivot | S1 | S2 | S3 |
|---|---|---|---|---|---|---|---|
| Classic | ₹580.39 | ₹538.97 | ₹509.14 | ₹467.72 | ₹437.89 | ₹396.47 | ₹366.64 |
| Fibonacci | ₹538.97 | ₹511.75 | ₹494.94 | ₹467.72 | ₹440.5 | ₹423.69 | ₹396.47 |
| Camarilla | ₹498.89 | ₹492.36 | ₹485.83 | ₹467.72 | ₹472.77 | ₹466.24 | ₹459.71 |
Support/resistance levels for today, calculated from the previous trading day's high/low/close.
Absolute Returns
YTD
—
1 Week
+1.06%
1 Month
-6.0%
3 Months
+34.71%
6 Months
—
1 Year
—
2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.
Stock Vitals
Computed from the latest available annual financials.
Graham Number
₹275.19
Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.
DuPont ROE Breakdown
14.71%
Net margin 11.35% × asset turnover 0.81x × equity multiplier 1.6x
Company Overview
Sector
Healthcare
Market Cap
₹1,455 Cr
P/E (TTM)
26.6
ROE
16.4%
Book Value
₹138.0
Face Value
₹5.0
Source: Screener.in (Consolidated figures) — data as of 24 Sep 2026. Not investment advice.
TopFund Analysis
Fermenta Biotech Ltd. holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 66/100. The strongest factor is Financial Strength (100/100), while Liquidity (28/100) is the weakest area to weigh before deciding. Notably: Promoter holding is rising.
TopFund Score — Fundamentals Quality
66/100 — GoodData confidence: 78/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.
As of 28 Sep 2026 · How we calculate this →
Financial Strength
Growth
Valuation
Cash Flow
Corporate Governance
Momentum
Institutional Ownership
Business Quality
Risk & Volatility
Liquidity
From Screener.in
- −The company has delivered a poor sales growth of 6.85% over past five years.
- −Company has a low return on equity of 12.6% over last 3 years.
- −Working capital days have increased from 48.7 days to 96.2 days
Not investment advice — an automated read of public fundamentals data, for research context only.
Corporate Actions
Copy of Newspaper Publication regarding notice to equity shareholders for transfer of shares to IEPF.
Fermenta Biotech notifies shareholders to claim unclaimed 2019-20 interim dividend by 18 Nov 2026 before IEPF transfer.
Fermenta signed exclusive licence with VIT Vellore for Vitamin B12 fortification technology on 8 September 2026.
Source: BSE regulatory filings, via Screener.in.
Quarterly Results
Last several quarters
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 82 | 57 | 99 | 97 | 78 | 95 | 156 | 140 | 136 | 130 | 137 | 122 | 122 |
| Expenses + | 72 | 71 | 74 | 92 | 77 | 76 | 103 | 103 | 108 | 104 | 112 | 102 | 104 |
| Operating Profit | 11 | -14 | 25 | 5 | 1 | 19 | 53 | 37 | 28 | 27 | 25 | 20 | 18 |
| OPM % | 13.26% | -24.44% | 25.39% | 5.53% | 1.02% | 19.76% | 34.04% | 26.42% | 20.73% | 20.46% | 18.17% | 16.45% | 14.83% |
| Other Income + | 2 | -6 | 3 | 5 | 3 | 3 | 2 | 4 | 9 | 5 | 1 | 14 | 4 |
| Interest | 5 | 4 | 5 | 3 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 3 |
| Depreciation | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 5 | 5 |
| Profit before tax | 2 | -29 | 16 | 1 | -6 | 12 | 45 | 32 | 28 | 24 | 17 | 26 | 15 |
| Tax % | 0.0% | 0.0% | 37.81% | 884.62% | 0.0% | 5.92% | 16.43% | -4.19% | 23.07% | 25.17% | 31.24% | 29.03% | 35.13% |
| Net Profit + | 2 | -29 | 10 | -7 | -6 | 11 | 38 | 33 | 22 | 18 | 12 | 19 | 10 |
| EPS in Rs | 1 | -10 | 3 | -2 | -2 | 4 | 13 | 12 | 7 | 6 | 4 | 7 | 3 |
| Raw PDF | — | — | — | — | — | — | — | — | — | — | — | — | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Profit & Loss (Yearly)
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 142 | 155 | 164 | 302 | 403 | 292 | 376 | 397 | 349 | 335 | 468 | 523 | 511 |
| Expenses + | 126 | 134 | 152 | 209 | 248 | 225 | 293 | 335 | 330 | 307 | 352 | 422 | 421 |
| Operating Profit | 16 | 21 | 12 | 93 | 156 | 66 | 83 | 62 | 18 | 28 | 115 | 101 | 90 |
| OPM % | 11.0% | 13.0% | 7.0% | 31.0% | 39.0% | 23.0% | 22.0% | 16.0% | 5.0% | 8.0% | 25.0% | 19.0% | 18.0% |
| Other Income + | 0 | 1 | 3 | 9 | 6 | 12 | 8 | 8 | -20 | 4 | 7 | 29 | 25 |
| Interest | 4 | 6 | 10 | 14 | 21 | 20 | 19 | 18 | 21 | 17 | 15 | 13 | 11 |
| Depreciation | 9 | 8 | 10 | 12 | 12 | 15 | 20 | 26 | 28 | 25 | 24 | 22 | 21 |
| Profit before tax | 3 | 7 | -6 | 76 | 129 | 43 | 52 | 27 | -51 | -10 | 83 | 96 | 82 |
| Tax % | 67.0% | 61.0% | 49.0% | 28.0% | 8.0% | -37.0% | 18.0% | 44.0% | 4.0% | 143.0% | 8.0% | 27.0% | — |
| Net Profit + | 1 | 2 | -9 | 46 | 117 | 60 | 43 | 15 | -53 | -24 | 76 | 70 | 58 |
| EPS in Rs | 0 | 0 | -4 | 12 | 43 | 20 | 15 | 5 | -17 | -8 | 26 | 24 | 20 |
| Dividend Payout % | 249.0% | -51.0% | -5.0% | 2.0% | 1.0% | 24.0% | 16.0% | 23.0% | -7.0% | -16.0% | 9.0% | 15.0% | — |
Source: Screener.in — figures in ₹ Crores unless marked %.
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reserves | 129 | 128 | 142 | 122 | 246 | 295 | 346 | 358 | 301 | 274 | 348 | 392 |
| Borrowings + | 71 | 89 | 87 | 173 | 209 | 224 | 232 | 239 | 220 | 139 | 115 | 113 |
| Other Liabilities + | 60 | 70 | 75 | 87 | 92 | 80 | 94 | 96 | 102 | 120 | 137 | 128 |
| Total Liabilities | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
| Fixed Assets + | 85 | 168 | 172 | 177 | 178 | 200 | 263 | 299 | 267 | 269 | 227 | 220 |
| CWIP | 65 | 6 | 5 | 4 | 22 | 71 | 57 | 35 | 45 | 2 | 16 | 13 |
| Investments | 18 | 15 | 18 | 10 | 8 | 0 | 0 | 0 | 3 | 0 | 0 | 0 |
| Other Assets + | 94 | 99 | 112 | 193 | 344 | 342 | 367 | 373 | 321 | 277 | 372 | 414 |
| Total Assets | 262 | 288 | 307 | 385 | 551 | 614 | 687 | 707 | 637 | 548 | 614 | 648 |
| Equity Capital | 2 | 2 | 2 | 2 | 5 | 14 | 14 | 14 | 14 | 14 | 15 | 14 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 15 | 4 | 2 | 59 | 90 | 34 | 63 | 43 | 116 | 105 | 41 | 93 |
| Cash from Investing Activity + | -18 | -13 | 7 | -101 | -97 | -44 | -41 | -26 | -55 | -16 | 0 | -43 |
| Cash from Financing Activity + | 1 | 10 | -12 | 89 | 12 | -47 | -1 | -22 | -41 | -91 | -51 | -42 |
| Net Cash Flow | -2 | 1 | -4 | 47 | 6 | -57 | 21 | -4 | 19 | -1 | -10 | 8 |
| CFO/OP | 119 | 35 | 35 | 83 | 79 | 73 | 92 | 85 | 610 | 370 | 38 | 108 |
| Free Cash Flow | -20 | -25 | -17 | 42 | 55 | -34 | 7 | 6 | 76 | 86 | 38 | 63 |
Source: Screener.in — figures in ₹ Crores unless marked %.
Shareholding Pattern
Quarter-by-quarter — Promoters, FII, DII & public holding trend
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Aug 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Others | 1.89% | 1.89% | 1.82% | 1.47% | 0.94% | 0.89% | 0.89% | 1.14% | 1.9% | 2.58% | 2.55% | 2.55% |
| Public | 36.05% | 36.05% | 36.11% | 36.41% | 36.98% | 35.0% | 35.0% | 34.75% | 33.99% | 33.32% | 33.19% | 32.95% |
| Promoters | 62.06% | 62.06% | 62.06% | 62.06% | 62.06% | 64.08% | 64.08% | 64.08% | 64.08% | 64.08% | 64.08% | 64.09% |
| FII | 0.0% | 0.0% | 0.0% | 0.05% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.02% | 0.13% | 0.37% |
| DII | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.04% | 0.04% |
Source: Screener.in — quarterly shareholding disclosures.
Peers Comparison
Healthcare — ranked by market cap
| Company | Market Cap (Cr) | P/E | P/B | ROE |
|---|---|---|---|---|
| Fermenta Biotech Ltd. (this stock) | 1,455 | 26.6 | 3.58 | 16.4% |
| Amrutajan Health Ltd | 1,480 | 72.6 | 13.76 | 20.0% |
| Gujarat Kidney N Sup Sp L | 1,398 | 88.3 | 5.53 | 11.1% |
| Kopran Ltd | 1,378 | 55.2 | 2.6 | 4.91% |
| Gpt Healthcare Limited | 1,331 | 32.0 | — | 28.5% |
| Shalby Limited | 1,589 | 40.4 | 1.58 | 2.45% |
| Anlon Healthcare Limited | 1,655 | 52.3 | 7.18 | 18.4% |
Which Mutual Funds Hold Fermenta Biotech Ltd.?
Frequently Asked Questions about Fermenta Biotech Ltd.
Fermenta Biotech Ltd. (FERMENTA) closed at ₹479.3 on NSE on 28 September 2026, up 10.9 (2.33%) from the previous close.
Fermenta Biotech Ltd. trades on the NSE (National Stock Exchange of India) under the symbol FERMENTA.
Fermenta Biotech Ltd. has a trailing twelve-month P/E (price-to-earnings) ratio of 26.6.
Fermenta Biotech Ltd. has a dividend yield of 0.76%.
Fermenta Biotech Ltd.'s 52-week high is ₹580.0 and its 52-week low is ₹249.0.
Fermenta Biotech Ltd. has a market capitalisation of ₹1,455 crore.
Fermenta Biotech Ltd. has a TopFund Quality Score of 66/100 (Good), a composite of profitability, balance-sheet health, growth and valuation. This is an analytical score based on public data, not personalized investment advice — see the full breakdown below before deciding.
Community Sentiment
What are other investors saying about Fermenta Biotech Ltd.?
No votes yet — be the first to share your view.
Sign in to voteDiscussion
User-generated content — not investment advice, and not verified or endorsed by TopFund.
Sign in to join the discussionNo comments yet — start the discussion.